GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (FRA:6MX) » Definitions » PB Ratio

Eidos Therapeutics (FRA:6MX) PB Ratio : 37.37 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Eidos Therapeutics's share price is €101.00. Eidos Therapeutics's Book Value per Share for the quarter that ended in Sep. 2020 was €2.70. Hence, Eidos Therapeutics's PB Ratio of today is 37.37.

The historical rank and industry rank for Eidos Therapeutics's PB Ratio or its related term are showing as below:

FRA:6MX's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.385
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Eidos Therapeutics PB Ratio Historical Data

The historical data trend for Eidos Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics PB Ratio Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
PB Ratio
- - 3.18 12.94

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.21 12.94 10.76 11.63 15.69

Competitive Comparison of Eidos Therapeutics's PB Ratio

For the Biotechnology subindustry, Eidos Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eidos Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's PB Ratio falls into.



Eidos Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Eidos Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2020)
=101.00/2.703
=37.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Eidos Therapeutics  (FRA:6MX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Eidos Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eidos Therapeutics (FRA:6MX) Business Description

Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Eidos Therapeutics (FRA:6MX) Headlines

No Headlines